ClinicalTrials.gg
CompletedNCT00266006Updated Nov 18, 2016

Factor VIIa in Acute Intracerebral Haemorrhage

A Phase 2 interventional study of eptacog alfa (activated) in Acquired Bleeding Disorder and Intracerebral Haemorrhage, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage — 1 open to participants now, 2 under way, 2 of them phase 3. recombinant FVIIa · Cerebral Hemorrhage.

Enrollment
6th of 11
90 · median 90
Started
2006
the only one that year
Phase 2
8 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
5 of 11
Novo Nordisk A/S

Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, this one is the 6th largest by enrollment, is the only one that started in 2006, is one of 8 in phase 2, and was the 4th registered.

Cerebral Hemorrhage

457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

1 of the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, or all of them as a file.
02

Study summary

This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.

03

Conditions studied

  • Acquired Bleeding Disorder
  • Intracerebral Haemorrhage

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spontaneous ICH

Exclusion criteria

Exclusion Criteria:

  • Time of ICH onset > 3 hours
  • Patients with secondary ICH
  • Pre-existing disability
  • Hemophilia
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The Occurrence of thromboembolic serious adverse event

    Time frame: Until 90 days

Secondary outcomes

  1. Reducing disability and improving clinical outcome

  2. Reducing haematoma growth

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Tokyo, 1000005, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2005
First posted
Dec 15, 2005
Start
Jan 2006
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00266006
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 15, 2005
Start date
Jan 2006
Primary completion
Apr 2007
Completion
Apr 2007
Last update
Nov 18, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion